Regulation of Inflammatory Genes in Hidradenitis Suppurativa

ConditionHidradenitis Suppurativa

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-89

SponsorUniversity of Alabama at Birmingham

About this trial

The purpose of this protocol is to examine the cytokine profi le of pati ents with hidradeniti s suppurati va (HS) and idemechanisms responsible for post-transcripti onal regulati on of these genes. The primary objecti ve is to determinfollowing cytokines linked to hidradeniti s suppurati va are diff erenti ally expressed in hidradeniti s pati ents versus controlalso doing a sub-study to determine the eff ect of childhood trauma on HS. The parti cipati on in the sub-study is opti onal

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosed with hidradenitis suppurativa

Not Pregnant

Disqualifiers

Mild/general dermatological issues like moles, other cosmetic issues

Patients with hidradenitis suppurativa, psoriasis, roasacea, atopic dermatitis and other inflammatory skin disease

Pregnant

Trial population

Hidradenitis suppurativa is an autoinflammatory skin disorder.They are difficult-to-heal and often scar. Hidradenitis suppurativa also has a significant psychological impact, and many patients suffer depression, anxiety, and impaired body-image. A hallmark of hidradenitis suppurativa is increased levels of biomarkers, which are molecules found in blood, other body fluids, or tissues that can be a sign of a normal or abnormal process. In hidradenitis suppurativa, these biomarkers are called "cytokines" and their job is to trigger the disease and make it worse.

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

Mental health
Behavioral
Early life exposure to abuse and development of hidradenitis suppurativa

Treatment groups

200 Participants

are divided into 2 treatment groups

Group A: Control1 intervention

Group B: Patients with HS1 intervention

Trial outcomes

Primary outcomes

Inflammatory biomarkers

Time frame

24 hours after application

Secondary outcomes

Cytokines

Time frame

24 hours after application

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Alabama at Birmingham

Lead sponsor

Source ClinicalTrials.gov

Apply now